[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 346,053
  • Shares Outstanding, K 268,258
  • Annual Sales, $ 236,200 K
  • Annual Income, $ -5,350 K
  • EBIT $ 5 M
  • EBITDA $ 7 M
  • 60-Month Beta 0.26
  • Price/Sales 1.50
  • Price/Cash Flow N/A
  • Price/Book 12.94
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.03 on 05/07/26
  • Next Earnings Date 08/05/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 218.86% (+47.45%)
  • Historical Volatility 103.22%
  • IV Percentile 83%
  • IV Rank 42.24%
  • IV High 442.51% on 02/19/26
  • IV Low 55.31% on 05/18/26
  • Expected Move (DTE 14) 0.1105 (11.58%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 1,999
  • Volume Avg (30-Day) 599
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 31,842
  • Open Int (30-Day) 33,352
  • Expected Range 0.8439 to 1.0649

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 2
  • High Estimate $-0.02
  • Low Estimate $-0.04
  • Prior Year $0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8500 +12.28%
on 08/06/26
1.4600 -34.63%
on 07/09/26
-0.3456 (-26.58%)
since 07/06/26
3-Month
0.8227 +16.01%
on 06/10/26
1.4600 -34.63%
on 07/09/26
-0.5256 (-35.51%)
since 05/06/26
52-Week
0.8227 +16.01%
on 06/10/26
3.4400 -72.26%
on 08/11/25
-2.8306 (-74.78%)
since 08/06/25

Most Recent Stories

More News
Akebia Therapeutics: Q2 Earnings Snapshot

Akebia Therapeutics: Q2 Earnings Snapshot

AKBA : 0.9544 (-26.02%)
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Q2 2026 Vafseo ® (vadadustat) net product revenues grew to  $21.3 million ; more than 10,500 p atients now on therapy Advancement of rare kidney disease pipeline continues with initiation...

AKBA : 0.9544 (-26.02%)
Akebia Therapeutics Enters Earnings With Its Commercial Execution Narrative Still Unproven

Barchart Research What to Expect from AKBA Earnings AKBA Generated August 4, 2026 Current Price $1.3200 EPS Estimate $$-0.03 Consensus Rating Strong Buy Average Move 10.38% Akebia Therapeutics Enters Earnings...

AKBA : 0.9544 (-26.02%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) --   Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 0.9544 (-26.02%)
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.9544 (-26.02%)
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2026 on...

AKBA : 0.9544 (-26.02%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 0.9544 (-26.02%)
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Vafseo ® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation...

AKBA : 0.9544 (-26.02%)
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 0.9544 (-26.02%)
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near

Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside...

AKBA : 0.9544 (-26.02%)

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 1.1863
2nd Resistance Point 1.0981
1st Resistance Point 1.0263
Last Price 0.9544
1st Support Level 0.8663
2nd Support Level 0.7781
3rd Support Level 0.7063

See More

52-Week High 3.4400
Fibonacci 61.8% 2.4402
Fibonacci 50% 2.1314
Fibonacci 38.2% 1.8225
Last Price 0.9544
52-Week Low 0.8227

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.